We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+45.38%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.7B
AUM Growth
+$6.43B
Cap. Flow
-$298M
Cap. Flow %
-1.32%
Top 10 Hldgs %
85.22%
Holding
124
New
14
Increased
20
Reduced
17
Closed
10

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$116M
2
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$86.7M
3
ADCT icon
ADC Therapeutics
ADCT
+$64M
4
NVTA
Invitae Corporation
NVTA
+$48M
5
SYRE icon
Spyre Therapeutics
SYRE
+$20.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$416M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$101M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$36.8M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.74%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OYST
101
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$2.06M 0.01%
+71,428
New +$2.15M
CYPH
102
Cypherpunk Technologies Inc
CYPH
$63.1M
$2.04M 0.01%
97,845
– –
BLCM
103
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.85M 0.01%
249,123
– –
MTNB icon
104
Matinas BioPharma
MTNB
$1.83M
$1.62M 0.01%
41,928
-33,156
-44% -$1.27M
GLMD icon
105
Galmed Pharmaceuticals
GLMD
$4.31M
$1.03M ﹤0.01%
1,198
– –
AFMD
106
DELISTED
Affimed
AFMD
$923K ﹤0.01%
20,000
– –
INFI
107
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$525K ﹤0.01%
580,400
– –
MRKR icon
108
Marker Therapeutics
MRKR
$19.3M
$498K ﹤0.01%
24,051
-122,969
-84% -$2.69M
ADMS
109
DELISTED
Adamas Pharmaceuticals
ADMS
$442K ﹤0.01%
172,630
– –
GNFT
110
DELISTED
Genfit
GNFT
$156K ﹤0.01%
28,396
+1,700
+6% +$19.9K
VIRX
111
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$147K ﹤0.01%
15,905
– –
REPL icon
112
Replimune Group
REPL
$425M
$128K ﹤0.01%
+5,141
New +$90.9K
CTMX icon
113
CytomX Therapeutics
CTMX
$690M
– –
-20,000
Closed -$153K
IDYA icon
114
IDEAYA Biosciences
IDYA
$3.43B
– –
-126,611
Closed -$522K
NERV icon
115
Minerva Neurosciences
NERV
$192M
– –
-86,066
Closed -$4.14M
TPST icon
116
Tempest Therapeutics
TPST
$14M
– –
-4,274
Closed -$4.4M
URGN icon
117
UroGen Pharma
URGN
$1.97B
– –
-672,912
Closed -$12M
VYNE icon
118
VYNE Therapeutics
VYNE
– –
-174
Closed -$1.68M
GTHX
119
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-88,026
Closed -$970K
HARP
120
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-20,447
Closed -$2.37M
RARX
121
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-2,093,839
Closed -$101M
BDSI
122
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-1,638,334
Closed -$6.21M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Baker Bros. Advisors held 124 positions worth $22.7B, up 40% from $16.2B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q2 2020 filing shows 14 new, 20 increased, 17 reduced and 10 closed positions. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M. The largest sale was Seagen Inc. Common Stock, an estimated $416M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M.
  • Baker Bros. Advisors added most to MyoKardia, Inc. Common Stock in Q2 2020, an estimated $116M increase.
  • Baker Bros. Advisors's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $416M.
  • Baker Bros. Advisors fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $101M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $22.7B portfolio in Q2 2020.
  • Baker Bros. Advisors opened 14 new positions and closed 10 in Q2 2020.
  • Baker Bros. Advisors's portfolio value rose 40% quarter-over-quarter to $22.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.